Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim in untreated aplastic anemia
NCT03957694Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Apr 2019
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of romiplostim in aplastic anemia, sponsored by Kyowa Kirin. Primary endpoint: Achievement of complete response (CR) or partial response (PR) at 27 weeks. Started Apr 2019; status: completed.
02
Drugs
romiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT03957694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03957694.